Authors
Latest:
The Virtual Window: Clinical Trial Reports--March 2007Successful research into new therapies for cancer requires a ready supply of patients willing to participate in clinical trials, and physicians and other health care professionals who will refer their patients to the appropriate studies.
Latest:
Personalizing Treatment for HPV-Related Head and Neck CancerOver the past decade, it has become apparent that head and neck squamous cell carcinoma-including cancers of the mouth, throat, and larynx-is actually two separate diseases.
Latest:
Findings Support Early Use of CD19 CAR T-Cell Therapy in Relapsed B-cell ALLLow disease burden prior to treatment with CD19-specific chimeric antigen receptor T-cell therapy appears to be a positive prognostic factor for long-term survival outcomes of patients with relapsed B-cell acute lymphoblastic leukemia.
Latest:
Predicting Treatment Outcomes in Older Adults With AMLMeasurable patient characteristics that predict better tolerance have not been widely studied and are desperately needed in clinical practice to inform treatment decision-making and individualize care for each older adult with AML.
Latest:
Staying Focused in Turbulent TimesWhen the market is volatile, people think about their financial future. With current market events as turbulent as they are, you may be concerned about their potential impact on your 401(k) account. During times like this, it is more important than ever to follow certain basic, time-tested principles of investing.
Latest:
The Management of Oral Mucositis in OncologyOral mucositis is a costly consequence of cancer therapy that can impede the efficacy of anticancer therapy. Simple preventive measures can greatly improve the patient�s outcome and quality of life.
Latest:
Changing the Face of Lung Cancer in Kentucky: New Program May Serve as National ModelThe efforts of the Kentucky LEADS Collaborative offer a unique opportunity to change the face of lung cancer in Kentucky by harnessing new lung cancer care and control strategies.
Latest:
SABCS Studies Highlight Promise and Complexity in Targeting PI3K in Breast CancerAlthough there is a significant scientific rationale for targeting the PI3K pathway in breast cancer, research findings presented recently at the 2014 San Antonio Breast Cancer Symposium (SABCS) highlight the inherent complexities in using agents directed at this cell-signaling network.
Latest:
Scientists Closer to Effectively Using Cord Blood to Treat Patients with CancerScientists at Fred Hutchinson Cancer Research Center in Seattle, Washington, successfully tested a mechanism that increases the number of progenitor cells extracted from a unit of human umbilical cord blood. The laboratory method potentially solves the 1- to 2-month delay in myeloid engraftment after cord blood transplantation (CBT).
Latest:
Healthy Lifestyle May Reduce Likelihood of Lethal Prostate Cancer Among Those With High Genetic RiskMaintaining a healthy lifestyle was found to reduce the likelihood of developing metastatic disease or dying of prostate cancer among men who had a high genetic risk.
Latest:
Lack of Discontinuation of Statin Therapy After Diagnosis of End-Stage CancerThe diagnosis of end-stage cancer rarely led to the clinically indicated discontinuation of statin therapy when prescribed for primary prevention.
Latest:
Tissue Truly Is the Issue in Advanced Non-Small Cell Lung CancerThe pathologic analysis of lung cancer has become increasingly complex, calling for continued attention to improving the accuracy of the assessment and reducing the amount of tissue required.
Latest:
Pegylated Liposomal Doxorubicin (Doxil) and Drug Combinations in Multiple MyelomaCurrent treatment approaches for mutiple myeloma focus on improving progression-free and overall survival. Although five-year survival rates have increased significantly over the past ten years, the prognosis of the disease is generally poor. The availability of several promising new therapies offers clinicians treatment options to further improve response rates, especially through the development of new combination regimens.
Latest:
BIO-BUZZ: Inhibition of Angiogenesis with Bevacizumab Shows Promise in the Treatment of Recurrent or Advanced Non%u2013Small-Cell Lung CancerThis year in the US, the American Cancer Society estimates that lung cancer will kill more people than breast, prostate, colon, liver, and kidney cancers combined, making it the leading cause of cancer death among Americans.
Latest:
News Reports: June 2007The articles featured in this issue are: 1) Supplemental Drug Application Submitted for Postoperative Nausea and Vomiting by John D. Zoidis, MD 2) Medicare Proposes Limits on Coverage for Erythropoiesis-Stimulating Drugs by John D. Zoidis, MD 3) Femara Reduces Risk of Early Breast Cancer Relapse in Postmenopausal Women, and more
Latest:
Five-year Follow-Up of 300 Patients Treated with Fludarabine, Cyclophosphamide, and Rituximab as Initial Therapy of CLLFinal results for the complete cohort of 300 patients with chronic lymphocytic leukemia (CLL) receiving the FCR (fludarabine, cyclophosphamide, and rituximab)regimen were presented at this year%u2019s American Society of Clinical Oncology meeting.
Latest:
Influential Online CommunitiesAs we begin 2009, I am struck by how radically different the Internet looks and acts today compared to just 10 years ago.
Latest:
Amonafide Plus Cytarabine Fails To Meet Primary EndpointAmonafide+Cytarabine may not be effective for secondary acute myeloid leukemia, according to ACCEDE trial data
Latest:
COME HOME Program Set to Save $33.5M Over 3 YearsIn an interview with Oncology Business Management, Barbara L. McAneny, MD, explains how the program will address fragmented care, suboptimal outcomes, high costs, and patient dissatisfaction.
Latest:
Nurse-Driven Website Empowers Nurses to Improve Patient CareImproving communication, building relationships, coordinating activities among units, and engaging staff members are not only ways to create a more positive working environment, they are critical for maintaining patient safety.
Latest:
Higher-Risk Myelodysplastic Syndromes: Lacking Treatment Advances in Over a DecadeContinued research is critical to potentially bring a targeted therapeutic option to patients with higher-risk myelodysplastic syndromes, to improve overall survival, manage symptoms, and preserve quality of life.
Latest:
Ablative Therapies for Small Renal MassesA peer-reviewed summary of the ablative techniques currently available for the treatment of small renal masses.
Latest:
Novel VIL Approach Reduces Complications From Regional Lymphadenectomy in MelanomaSurgical intervention is a Machiavellian endeavor: the ends justify the means. This obligates the clinician to minimize the risk of a procedure to justify the gains obtained from an intervention.
Latest:
Pancoast Tumors of the Lung: Improved ResultsEvery patient with a pancoast tumor of the lung should be evaluated by a Pancoast-experienced thoracic surgeon (and neurosurgeon) before ruling out surgery, and before starting induction therapy.
Latest:
Don't Forget the Partner of a Patient With CancerLinda Goodfellow, PhD, RN, of Duquesne University, discussing the important role nurses play in supporting the spouses of patients with cancer, a critical, yet often unmet need.
Latest:
Journal Club Bridges Research and Practice, Improving Patient CareThree oncology nurses at the Smilow Cancer Hospital at Yale-New Haven write about the Smilow Society, an interactive and innovative journal club enabling nurses to stay abreast of important research developments, which can then be translated directly into clinical practice.
Latest:
BRCA Testing and Contralateral Prophylactic MastectomyDetermination of BRCA1 and 2 mutation carrier status has become increasingly important. Estimates suggest that about 80% of breast cancers and 90% of ovarian cancers are sporadic; while only 5% to 10% of breast cancers are hereditary.
Latest:
Provide Your Patients with an Online Resource You can Both Trust...Your Own!Patients are going online for health information but would prefer to get it from you. Are you there to help them?
Latest:
Pomalidomide Shows Benefits in Trials Testing New CombinationsResults from a pair of phase II studies indicate that adding the immunomodulatory agent pomalidomide (Pomalyst) to multiple myeloma regimens improved outcomes for patients who have stopped responding to earlier treatments.
